Abstract
Cyclic AMP is an ubiquitous molecule that serves as an important second messenger for multiple signaling pathways. At least nine membrane-bound mammalian isoforms of adenylyl cyclase have been identified, and each isoform has a distinct pattern of tissue distribution as well as interaction with regulatory proteins within local cytosolic environment. Adenylyl cyclase is coupled to G-protein receptors and serves to convert ATP to cAMP. Although many of the upstream G-protein receptors and cAMP regulators such as phosphodiesterase have been utilized as targets of pharmacotherapy, the attempt of pharmacologic regulation of adenylyl cyclase itself has not been successful. Recent studies have characterized the distinct physiologic effect of each adenylyl cyclase isoform within different organ systems, suggesting the potential therapeutic utility of isoform-specific regulators of adenylyl cyclase. In the current review, we aim to discuss the effects of genetic regulation for each adenylyl cyclase isoform as well as the development of isoformspecific adenylyl cyclase regulators including their therapeutic potential.
Keywords: cAMP, adenylyl cyclase, P-site inhibitor, forskolin, phosphodiesterase, protein kinase A, G-protein coupled receptor, Epac, adenosine triphosphate, memory loss
Current Enzyme Inhibition
Title:Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase
Volume: 8 Issue: 2
Author(s): David Wei-Kang Ho, Masanari Umemura, Claudio Bravo and Kousaku Iwatsubo
Affiliation:
Keywords: cAMP, adenylyl cyclase, P-site inhibitor, forskolin, phosphodiesterase, protein kinase A, G-protein coupled receptor, Epac, adenosine triphosphate, memory loss
Abstract: Cyclic AMP is an ubiquitous molecule that serves as an important second messenger for multiple signaling pathways. At least nine membrane-bound mammalian isoforms of adenylyl cyclase have been identified, and each isoform has a distinct pattern of tissue distribution as well as interaction with regulatory proteins within local cytosolic environment. Adenylyl cyclase is coupled to G-protein receptors and serves to convert ATP to cAMP. Although many of the upstream G-protein receptors and cAMP regulators such as phosphodiesterase have been utilized as targets of pharmacotherapy, the attempt of pharmacologic regulation of adenylyl cyclase itself has not been successful. Recent studies have characterized the distinct physiologic effect of each adenylyl cyclase isoform within different organ systems, suggesting the potential therapeutic utility of isoform-specific regulators of adenylyl cyclase. In the current review, we aim to discuss the effects of genetic regulation for each adenylyl cyclase isoform as well as the development of isoformspecific adenylyl cyclase regulators including their therapeutic potential.
Export Options
About this article
Cite this article as:
Wei-Kang Ho David, Umemura Masanari, Bravo Claudio and Iwatsubo Kousaku, Recent Advance in Isoform-Specific Regulation of Adenylyl Cyclase, Current Enzyme Inhibition 2012; 8 (2) . https://dx.doi.org/10.2174/157340812800793282
DOI https://dx.doi.org/10.2174/157340812800793282 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Update on the Evaluation and Management of Brief Resolved Unexplained Events (Previously Apparent Life-Threatening Events)
Reviews on Recent Clinical Trials Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Magnesium and Anaesthesia
Current Drug Targets Doxorubicin Loaded Dextran-coated Superparamagnetic Iron Oxide Na-noparticles with Sustained Release Property: Intracellular Uptake, Phar-macokinetics and Biodistribution Study
Current Pharmaceutical Biotechnology Prognostic Utility of Troponin I and N Terminal-ProBNP among Patients with Heart Failure due to Non-Ischemic Cardiomyopathy and Important Correlations
Cardiovascular & Hematological Agents in Medicinal Chemistry Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Current Alzheimer Research The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Mining for Protein Kinase Substrates: Integration of Biochemistry, Genetics and Proteomics
Current Proteomics The Association Between HIV/AIDS During Pregnancy and Fetal Growth Parameters in Florida: A Population Based Study
Current HIV Research Nicotine Addiction and Coronary Artery Disease: Impact of Cessation Interventions
Current Pharmaceutical Design Therapeutic Management of COVID-19 Patients: Clinical Manifestation and Limitations
Current Pharmaceutical Design Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science Editorial [Hot Topic Cardiovascular and Metabolic Diseases: from Mechanisms to Novel Therapeutical Implications Guest Editors: Attila Borbély and Pawel Petkow Dimitrow]
Current Pharmaceutical Biotechnology Cardiovascular Manifestations of COVID-19
Current Cardiology Reviews A Review on Electrocardiographic Changes in Diabetic Patients
Current Diabetes Reviews Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19
Current Drug Targets Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry